MediWound Ltd. (MDWD)
NASDAQ: MDWD · Real-Time Price · USD
18.34
-0.03 (-0.16%)
At close: Nov 4, 2024, 4:00 PM
18.50
+0.16 (0.87%)
After-hours: Nov 4, 2024, 7:59 PM EST
MediWound Employees
MediWound had 100 employees as of December 31, 2023. The number of employees increased by 17 or 20.48% compared to the previous year.
Employees
100
Change (1Y)
17
Growth (1Y)
20.48%
Revenue / Employee
$201,410
Profits / Employee
-$199,730
Market Cap
197.82M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Nevro | 1,215 |
| LifeMD | 211 |
| Electromed | 174 |
| ProKidney | 163 |
| Gossamer Bio | 135 |
| Senseonics Holdings | 132 |
| Kodiak Sciences | 111 |
| Cabaletta Bio | 103 |
MDWD News
- 6 days ago - MediWound Is A Healthy Investment - Seeking Alpha
- 26 days ago - MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers - GlobeNewsWire
- 2 months ago - MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns - GlobeNewsWire
- 2 months ago - MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update - GlobeNewsWire
- 3 months ago - MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT) - GlobeNewsWire
- 3 months ago - MediWound to Report Second Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers - GlobeNewsWire